secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001213900-25-014351
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports wider Q1 net loss of $6.7M; engaged Jefferies for strategic alternatives
--------------------------------------------------------------------------------

- Net loss of $6.7M ($0.09/share) vs $4.7M ($0.07) in Q1 fiscal 2024.
- G&A expenses rose to $3.3M from $1.5M on pre-commercial launch costs for LYMPHIR.
- Engaged Jefferies as exclusive financial advisor to evaluate strategic alternatives; active discussions underway.
- Received permanent J-code J9161 for LYMPHIR effective April 1, 2025; launch on track for H1 2025.
- R&D expenses were $1.3M, up from $1.2M, supporting two investigator-initiated trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025014351/0001213900-25-014351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025014351/ea0231246-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-014351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer